Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 11/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.45 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | PRKACG | P22612 | 2/20 | 0.44 |
| ▸ | PRKACB | P22694 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25930772 | 0.93 | TDP1 (0.59) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930822 | 0.93 | TDP1 (0.57) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930563 | 0.91 | TDP1 (0.57) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930837 | 0.89 | TDP1 (0.58) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930507 | 0.88 | TDP1 (0.57) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930652 | 0.87 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930757 | 0.86 | TDP1 (0.57) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930575 | 0.86 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930915 | 0.86 | TDP1 (0.64) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20015943 | 0.86 | TDP1 (0.74) | TDP1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | PDE6C, PDE2A, GMPS | TDP1 1835/4885PDE4A 19/4885PDE4B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.